

Jubilant Drug Development Pte. Ltd
Balance Sheet as at 31 March 2017

	Notes No	As at 31 March 2017		As at 31 March 2016		As at 1 April 2015	
		USD	(INR'000)	USD	(INR'000)	USD	(INR'000)
ASSETS							
Non-Current assets							
Financial assets							
Non-current investments	1	2,478,416	160,725	2,478,416	164,195	2,478,416	154,901
Long-term loans and advances		3,579	232	3,720	246	3,636	227
Total non-current assets		2,481,995	160,957	2,482,136	164,441	2,482,052	155,128
Current assets							
Cash and cash equivalents	2	2,865	186	2,905	192	2,905	182
Other current assets	3	1,792	116	1,768	118	-	-
Total Current assets		4,657	302	4,673	310	2,905	182
Total Assets		2,486,652	161,259	2,486,809	164,751	2,484,957	155,310
EQUITY AND LIABILITIES							
Equity							
Equity share capital	4	2,547,001	127,332	2,547,001	127,332	2,547,001	127,332
Other equity	5	(99,659)	31,378	(86,591)	35,670	(74,910)	27,174
Total equity		2,447,342	158,710	2,460,410	163,002	2,472,091	154,506
Liabilities							
Current liabilities							
Financial liabilities							
Trade payables	6	39,310	2,549	26,399	1,749	12,866	804
Total current liabilities		39,310	2,549	26,399	1,749	12,866	804
Total Equity and Liabilities		2,486,652	161,259	2,486,809	164,751	2,484,957	155,310

Prakash C Bisht
CFO (LSI) & Senior VP (Group Accounts)
Place: Noida
Date: 23 May, 2017

Jubilant Drug Development Pte. Ltd
Statement of Profit and Loss for the year ended 31 March 2017

	Notes No	For the year ended 31 March 2017		For the year ended 31 March 2016	
		USD	(INR'000)	USD	(INR'000)
EXPENSES					
Other expenses	7	(13,068)	(877)	(11,681)	(763)
Total expenses		(13,068)	(877)	(11,681)	(763)
(Loss) for the Year		(13,068)	(877)	(11,681)	(763)
Items that will be reclassified to profit or loss					
Exchange difference on translation of foreign operations		-	(3,416)	-	40,381
Total other comprehensive Income , net of tax		-	(3,416)	-	40,381
Total comprehensive Income for the year		(13,068)	(4,293)	(11,681)	39,618
Profit attributable to :					
Owners of the company		(13,068)	(877)	(11,681)	(763)
Non-controlling Interest		(13,068)	(877)	(11,681)	(763)
Total comprehensive Income attribute to:					
Owners of the company		(13,068)	(4,293)	(11,681)	39,618
Non-controlling Interest		(13,068)	(4,293)	(11,681)	39,618

Prakash C Bisht
CFO (LSI) & Senior VP (Group Accounts)
Place: Noida
Date: 23 May, 2017

Jubilant Drug Development Pte. Ltd

Cash flow statement for the Year ended on 31 March 2017

Particulars	For the year ended on 31 March 2017		For the year ended on 31 March 2016	
	USD	(INR'000)	USD	(INR'000)
A. Cash flow from operating activities				
(Loss) before tax	(13,068)	(877)	(11,681)	(763)
Operating cash flow before working capital changes				
Decrease/ Increase in trade receivable, other non-current assets, current assets and other financial assets	118	8	(1,852)	(113)
Increase in trade payables and current liabilities	12,910	866	13,533	828
Cash generated from operations	(40)	(3)	-	(49)
Income tax paid (net of refund)	-	-	-	-
Net cash generated from operating activities	(40)	(3)	-	(49)
B. Effect of exchange rate changes		(3)		59
Net decrease in cash and cash equivalents (A+B)	(40)	(6)	-	10
Add: cash and cash equivalents at the beginning of year	2,905	192	2,905	182
Cash and cash equivalents at the end of the year	2,865	186	2,905	192
<i>Reconciliation of cash and cash equivalents as per the cash flow statement</i>				
Cash and cash equivalents	2,865	186	2,905	192
Bank overdrafts				
Balances per statement of cash flows	2,865	186	2,905	192

Prakash C Bisht

CFO (LSI) & Senior VP (Group Accounts)

Place: Noida

Date: 23 May, 2017

Jubilant Drug Development Pte. Ltd
Notes to financial statements for the year 31 March 2017

	As at 31 March 2017		As at 31 March 2016		As at 1-April-2015	
	USD	(INR'000)	USD	(INR'000)	USD	(INR'000)
1. Non-current Investments						
Investment In Subsidiary/Fellow Subsidiaries Companies						
Jubilant Chemsys Limited 1,999,766 (31 March 2016: 1,999,766; 1 April 2015: 1,999,766 of Rs. 10 each)	2,076,349	134,651	2,076,349	137,558	2,076,349	129,772
Jubilant Clinsys Limited 1,999,766 (31 March 2016: 1,999,766; 1 April 2015: 1,999,766 of Rs. 10 each)	402,067	26,074	402,067	26,637	402,067	25,129
	2,478,416	160,725	2,478,416	164,195	2,478,416	154,901
2. CASH AND CASH EQUIVALENTS						
Cash and cash equivalents						
Balances with banks:						
- On current accounts	2,865	186	2,905	192	2,905	182
	2,865	186	2,905	192	2,905	182
3. OTHER CURRENT ASSETS						
Prepaid expenses	1,792	116	1,768	118	-	-
	1,792	116	1,768	118	-	-

Jubilant Drug Development Pte. Ltd
Notes to financial statement for the year 31 March 2017

	As at 31 March 2017		As at 31 March 2016		As at 1-April-2015	
	USD	(INR'000)	USD	(INR'000)	USD	(INR'000)
4. SHARE CAPITAL						
Issued & Subscribed						
2,547,001 (31 March 2016; 2,547,001; 1 April 2015; 2,547,001 equity shares with USD 1 par value)	2,547,001	127,332	2,547,001	127,332	2,547,001	127,332
	2,547,001	127,332	2,547,001	127,332	2,547,001	127,332
Paid up						
2,547,001 (31 March 2016; 2,547,001; 1 April 2015; 2,547,001 equity shares with USD 1 par value)	2,547,001	127,332	2,547,001	127,332	2,547,001	127,332
	2,547,001	127,332	2,547,001	127,332	2,547,001	127,332

Movement in equity share capital

Particulars	As at 31 March 2017		As at 31 March 2016		As at 1 April 2015	
	Number	(INR'000)	Number	(INR'000)	Number	(INR'000)
At the commencement and at the end of the year	2,547,001	127,332	2,547,001	127,332	2,547,001	127,332

Terms and rights attached to equity shares

The Company has only one class of shares referred to as equity shares having par value of USD 1 each. Each holder of equity shares is entitled to one vote per share. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company, after distribution of all preferential amounts. However, no such preferential amounts exist currently. The distribution will be in proportion to the number of equity shares held by the shareholders.

The details of shareholders holding more than 5% shares in the company

Name of the shareholder	As at 31 March 2017		As at 31 March 2016		As at 1 April 2015	
	Number	% of total shares	Number	% of total shares	Number	% of total shares
Jubilant Life Science (BVI) Limited	2,547,001	100%	2,547,001	100%	2,547,001	100%

Jubilant Drug Development Pte. Ltd
Notes to financial statement for the year 31 March 2017

	As at 31 March 2017		As at 31 March 2016		As at 1-April-2015	
	USD	(INR'000)	USD	(INR'000)	USD	(INR'000)
5. OTHER EQUITY						
Retained earning						
Opening balance	(86,591)	26,411	(74,910)	27,174	(61,728)	27,980
Add: Net loss after tax transferred from Statement of Profit and Loss	(13,068)	(877)	(11,681)	(763)	(13,182)	(806)
Amount available for appropriation	(99,659)	25,534	(86,591)	26,411	(74,910)	27,174
Exchange differences on translation of foreign operations						
Opening balance	-	9,260	-	-	-	-
Addition/(deduction) during the year	-	(3,416)	-	9,260	-	-
At the end of the year	-	5,844	-	9,260	-	-
	(99,659)	31,378	(86,591)	35,670	(74,910)	27,174
6. TRADE PAYABLES						
Trade payables-others	39,310	2,549	26,399	1,749	12,866	804
	39,310	2,549	26,399	1,749	12,866	804

Jubilant Drug Development Pte. Ltd

Notes to the financial statements for the year 31 March 2017

	For the year ended 31 March 2017		For the year ended 31 March 2016	
	USD	(INR'000)	USD	(INR'000)
7. OTHER EXPENSE				
Auditors remuneration	3,756	252	4,001	262
Legal , professional and consultancy charges	9,131	612	7,764	507
Bank charges	40	3	-	-
Foreign exchange loss/(gain)	141	10	(84)	(6)
	13,068	877	11,681	763